Watch for FDA decisions on pending BLAs for AVT05, AVT06, AVT03, and AVT16/AVT80, as the VAI classification and DSM2 approval signal improved regulatory standing. Each approval could unlock additional U.S. market launches and revenue streams.
Price Chart
Executive Summary
FDA approved a supplement to Alvotech's BLA for AVT02 (SIMLANDI®), enabling drug substance manufacturing in a second production suite (DSM2) at its Reykjavik facility. This doubles U.S. commercial supply capacity and confirms resolution of inspection issues, paving the way for FDA action on pending BLAs for AVT05, AVT06, AVT03, and AVT16/AVT80.
Key Facts
- FDA approved supplement to BLA for AVT02 (adalimumab-ryvk), marketed as SIMLANDI® in the U.S.
- Approval enables drug substance manufacturing in second production suite (DSM2) at Reykjavik facility.
- DSM2 doubles drug substance manufacturing capacity available for U.S. supply.
- Approval follows FDA's July 2026 closure of Reykjavik inspection with Voluntary Action Indicated (VAI) classification.
- Alvotech expects FDA to act on pending BLAs for AVT05 (golimumab biosimilar), AVT06 (aflibercept biosimilar), AVT03 (denosumab biosimilar), and AVT16/AVT80 (vedolizumab biosimilars) according to their goal dates.
- DSM2 already approved for commercial drug substance manufacturing for European markets for AVT02, AVT03, and AVT05.
Financial Impact
Doubles U.S. commercial supply capacity for AVT02 (SIMLANDI®), a biosimilar to Humira®. No specific revenue figures provided.
Risk Factors
- Pending BLAs remain subject to individual FDA review and may not be approved.
- Commercial success of SIMLANDI® depends on market adoption and competition from other adalimumab biosimilars.
- Manufacturing or quality issues could recur at the Reykjavik facility.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3374199 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $5.12 | awaiting T+20 | — | $4.62 (−9.77%) |
Oct 14, 2026 12d ago | 6-K | $5.17 | awaiting T+20 | — | $4.62 (−10.64%) |
Oct 7, 2026 19d ago | 6-K | $5.85 | awaiting T+20 | — | $4.62 (−21.03%) |
Oct 5, 2026 22d ago | 6-K | $6.11 | awaiting T+20 | — | $4.62 (−24.39%) |
Oct 5, 2026 22d ago | Press Release | $6.11 | awaiting T+20 | — | $4.62 (−24.39%) |
Aug 31, 2026 8w ago | 6-K | $5.19 $5.92 | ▲ +14.07% | ▲ +14.44% | $4.62 (−10.98%) |
Aug 21, 2026 9w ago | 6-K | $4.43 $5.88 | ▲ +32.73% | ▲ +31.72% | $4.62 (+4.29%) |
Aug 19, 2026 9w ago | Press Release | $4.27 $5.87 | ▼ −37.47% | ▼ −37.59% | $4.62 (−8.20%) |
Jul 29, 2026 12w ago | 6-K | $3.53 $4.91 | ▲ +39.09% | ▲ +34.07% | $4.62 (+30.88%) |
Jul 3, 2026 16w ago | Press Release | $3.46 $4.12 | ▲ +19.08% | ▲ +19.64% | $4.62 (+33.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers